234 related articles for article (PubMed ID: 21083471)
1. Plasma cell leukemia: concepts and management.
Liedtke M; Medeiros BC
Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
[TBL] [Abstract][Full Text] [Related]
2. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
3. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
[TBL] [Abstract][Full Text] [Related]
5. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
[TBL] [Abstract][Full Text] [Related]
6. Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
Awan FT; Osman S; Kochuparambil ST; Gibson L; Remick SC; Abraham J; Craig M; Jillella A; Hamadani M
Bone Marrow Transplant; 2012 Jan; 47(1):146-8. PubMed ID: 21358681
[No Abstract] [Full Text] [Related]
7. [Plasma cell leukemia].
Ravinet A; Bay JO; Tournilhac O
Bull Cancer; 2014 Nov; 101(11):1048-58. PubMed ID: 25418598
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma.
Kyle RA; Rajkumar SV
N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
[No Abstract] [Full Text] [Related]
9. Clinical impact of chromosomal aberrations in multiple myeloma.
Nahi H; Sutlu T; Jansson M; Alici E; Gahrton G
J Intern Med; 2011 Feb; 269(2):137-47. PubMed ID: 21158983
[TBL] [Abstract][Full Text] [Related]
10. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
11. [Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis].
Jurczyszyn A; Zawirska D; Skotnicki AB
Przegl Lek; 2011; 68(6):320-5. PubMed ID: 22039670
[TBL] [Abstract][Full Text] [Related]
12. Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.
Mele G; Pinna S; Melpignano A; Quarta G
Clin Ther; 2010 May; 32(5):915-9. PubMed ID: 20685499
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma - current issues and controversies.
Kumar S
Cancer Treat Rev; 2010 May; 36 Suppl 2():S3-11. PubMed ID: 20472186
[TBL] [Abstract][Full Text] [Related]
14. Emergence of central nervous system myeloma in the era of novel agents.
Gangatharan SA; Carney DA; Prince HM; Wolf MM; Januszewicz EH; Ritchie DS; Harrison SJ
Hematol Oncol; 2012 Dec; 30(4):170-4. PubMed ID: 22144117
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Musto P; Falcone A; Sanpaolo G; Guglielmelli T; Zambello R; Balleari E; Catalano L; Spriano M; Cavallo F; La Sala A; Mantuano S; Nobile M; Melillo L; Scalzulli PR; Dell'Olio M; Bodenizza C; Greco MM; Carella AM; Merla E; Carella AM; Boccadoro M; Cascavilla N; Palumbo A
Leuk Res; 2006 Mar; 30(3):283-5. PubMed ID: 16111749
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
17. [New treatment strategy of multiple myeloma for cure].
Murakami H; Handa H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
19. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
Mattei D; Mordini N; Vigna Taglianti R; Bruno B; Rapezzi D; Gallamini A
Haematologica; 2005 Jun; 90(6):861-2. PubMed ID: 15951306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
